Patrick A Flume

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3142683/publications.pdf

Version: 2024-02-01

118 papers	8,343 citations	81900 39 h-index	46799 89 g-index
120 all docs	120 docs citations	120 times ranked	6106 citing authors

#	Article	IF	Citations
1	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
2	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 957-969.	5.6	773
3	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 802-808.	5.6	634
4	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
5	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
6	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis, 2012, 11, 461-479.	0.7	421
7	Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. Chest, 2012, 142, 718-724.	0.8	290
8	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis, 2011, 10, 54-61.	0.7	284
9	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	6.7	253
10	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet, The, 2018, 392, 880-890.	13.7	247
11	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 298-306.	5.6	225
12	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 814-823.	5.6	212
13	Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respiratory Care, 2009, 54, 522-37.	1.6	204
14	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	10.7	197
15	Massive Hemoptysis in Cystic Fibrosis. Chest, 2005, 128, 729-738.	0.8	189
16	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Medicine,the, 2014, 2, 738-749.	10.7	172
17	Pneumothorax in Cystic Fibrosis. Chest, 2005, 128, 720-728.	0.8	136
18	Pulmonary Complications of Cystic Fibrosis. Respiratory Care, 2009, 54, 618-627.	1.6	120

#	Article	IF	Citations
19	Transition programs in cystic fibrosis centers: Perceptions of pediatric and adult program directors. Pediatric Pulmonology, 2001, 31, 443-450.	2.0	95
20	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.7	84
21	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis, 2017, 16, 600-606.	0.7	76
22	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2017, 16, 592-599.	0.7	69
23	Transition programs in cystic fibrosis centers: Perceptions of team members. Pediatric Pulmonology, 2004, 37, 4-7.	2.0	67
24	A Preliminary Quality of Life Questionnaire-Bronchiectasis. Chest, 2014, 146, 437-448.	0.8	66
25	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.7	66
26	Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects. Antimicrobial Agents and Chemotherapy, 2011, 55, 2636-2640.	3.2	63
27	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Journal of Pediatrics, 2015, 167, 1081-1088.e1.	1.8	63
28	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
29	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
30	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
31	State of progress in treating cystic fibrosis respiratory disease. BMC Medicine, 2012, 10, 88.	5.5	58
32	Pneumothorax in Cystic Fibrosis. Chest, 2003, 123, 217-221.	0.8	57
33	Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 2016, 71, 223-229.	5.6	53
34	Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 809-815.	0.7	50
35	Clinical applications of pulmonary delivery of antibiotics. Advanced Drug Delivery Reviews, 2015, 85, 1-6.	13.7	46
36	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46

#	Article	IF	Citations
37	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11â€¯years with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 708-713.	0.7	44
38	Inhaled alpha 1 -proteinase inhibitor therapy in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 227-233.	0.7	43
39	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials, 2018, 64, 35-40.	1.8	42
40	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis, 2016, 15, 634-640.	0.7	40
41	Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 321-325.	0.7	37
42	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis, 2018, 17, 83-88.	0.7	36
43	The role of 2,4-dihydroxyquinoline (DHQ) inPseudomonas aeruginosapathogenicity. PeerJ, 2016, 4, e1495.	2.0	36
44	Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 78-85.	0.7	35
45	The Rationale for Aerosolized Antibiotics. Pharmacotherapy, 2002, 22, 71S-79S.	2.6	34
46	A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. Journal of Cystic Fibrosis, 2022, 21, 721-724.	0.7	34
47	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Annals of the American Thoracic Society, 2019, 16, 534-539.	3.2	33
48	Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 1147-1157.	3.2	29
49	Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Scientific Reports, 2021, 11, 14232.	3.3	28
50	Smoothing the transition from pediatric to adult care: lessons learned. Current Opinion in Pulmonary Medicine, 2009, 15, 611-614.	2.6	26
51	A Pilot Study of the Efficacy of Constant-Infusion Ceftazidime in the Treatment of Endobronchial Infections in Adults with Cystic Fibrosis. Pharmacotherapy, 1999, 19, 620-626.	2.6	24
52	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
53	Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease. Chest, 2021, 160, 831-842.	0.8	24
54	Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 737-742.	0.7	22

#	Article	IF	Citations
55	Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. Journal of Cystic Fibrosis, 2022, 21, 777-783.	0.7	22
56	Pneumothorax in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 220-225.	2.6	21
57	Pulmonary Complications of Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 804-809.	2.1	21
58	Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe, 2015, 11, 39-48.	1.3	20
59	In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infectious Diseases, 2018, 5, ofy158.	0.9	20
60	Oneâ€year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatric Pulmonology, 2016, 51, 372-378.	2.0	18
61	Antimicrobial resistance in cystic fibrosis: Does it matter?. Journal of Cystic Fibrosis, 2018, 17, 687-689.	0.7	18
62	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
63	Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Review of Respiratory Medicine, 2018, 12, 585-593.	2.5	17
64	Respiratory Muscle Strength Training to Improve Vocal Function in Patients with Presbyphonia. Journal of Voice, 2022, 36, 344-360.	1.5	16
65	Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 407-414.	0.7	15
66	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respiratory Medicine, 2011, 105, S18-S23.	2.9	14
67	Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transplantation, 2001, 7, 1081-1084.	2.4	13
68	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
69	Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. Journal of Cystic Fibrosis, 2020, 19, 569-574.	0.7	12
70	Treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 679-684.	2.6	11
71	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. IScience, 2021, 24, 102489.	4.1	11
72	Bronchodilators in cystic fibrosis: a critical analysis. Expert Review of Respiratory Medicine, 2017, 11, 13-20.	2.5	10

#	Article	IF	Citations
73	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	7.1	10
74	Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation. Journal of Cystic Fibrosis, 2021, 20, 288-294.	0.7	10
75	Airway Clearance Techniques. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 727-736.	2.1	9
76	Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institutionâ€™s Experience. Journal of Empirical Research on Human Research Ethics, 2018, 13, 139-144.	1.3	9
77	Overcoming non-compliance with clinical trial registration and results reporting: One Institution's approach. Contemporary Clinical Trials Communications, 2020, 18, 100557.	1.1	9
78	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.8	9
79	Emergency Preparedness for the Chronically Ill. American Journal of Nursing, 2005, 105, 68-72.	0.4	8
80	Making the Diagnosis of Cystic Fibrosis. American Journal of the Medical Sciences, 2008, 335, 51-54.	1.1	8
81	Prioritizing Studies of COVID-19 and Lessons Learned. Journal of Clinical and Translational Science, 2021, 5, 1-27.	0.6	8
82	Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future. Chest, 2021, 160, 1232-1240.	0.8	8
83	Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?. Thorax, 2017, 72, 297-299.	5.6	7
84	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. Journal of Cystic Fibrosis, 2021, 20, 36-38.	0.7	7
85	Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. Journal of Cystic Fibrosis, 2021, 20, 1003-1009.	0.7	7
86	Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	2.0	7
87	Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutrition in Clinical Practice, 2022, 37, 344-350.	2.4	7
88	â€œPathogen Eradicationâ€•and â€œEmerging Pathogensâ€• Difficult Definitions in Cystic Fibrosis. Journal of Clinical Microbiology, 2018, 56, .	3.9	6
89	Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. Journal of Voice, 2022, 36, 673-684.	1.5	6
90	Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infectious Diseases, 2022, 22, 246.	2.9	6

#	Article	IF	Citations
91	A role for aerosolized antibiotics. Pediatric Pulmonology, 2008, 43, S29-S34.	2.0	5
92	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 246-248.	1.8	5
93	Clinical care for cystic fibrosis: preparing for the future now. Lancet Respiratory Medicine,the, 2020, 8, 10-12.	10.7	5
94	Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. Journal of Genetic Counseling, 2018, 27, 1049-1054.	1.6	4
95	Disruption in research publishing â€“ the open access revolution. Journal of Cystic Fibrosis, 2019, 18, 747-749.	0.7	4
96	Managing the risks and benefits of clinical research in response to a pandemic. Journal of Clinical and Translational Science, 2021, 5, .	0.6	4
97	Rheumatoid arthritis-associated bronchiectasis â€“ Authors' reply. Lancet, The, 2019, 393, 2036.	13.7	3
98	Seven P's of publication practices. Journal of Cystic Fibrosis, 2020, 19, 333-335.	0.7	3
99	Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest, 2021, 160, 2042-2050.	0.8	3
100	Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis, 2022, 21, 96-103.	0.7	2
101	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, , .	0.7	2
102	Efficacy measures for clinical trials: A review series. Journal of Cystic Fibrosis, 2016, 15, 415.	0.7	1
103	The challenges of maintaining momentum in CF drug development and approval - Commentary. Journal of Cystic Fibrosis, 2017, 16, 170-171.	0.7	1
104	The study of CFTR modulators in the very young. Lancet Respiratory Medicine,the, 2019, 7, 287-289.	10.7	1
105	Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. European Respiratory Journal, 2020, 55, 2000105.	6.7	1
106	1468. Culture Conversion and Mortality in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review. Open Forum Infectious Diseases, 2020, 7, S736-S736.	0.9	1
107	1488. Relationship Between Culture Conversion and Clinical Outcomes in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review. Open Forum Infectious Diseases, 2020, 7, S746-S746.	0.9	1
108	Learningâ€™s from the Editors Desk â€“ 2017. Journal of Cystic Fibrosis, 2017, 16, 645-646.	0.7	0

#	Article	IF	Citations
109	Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 575-577.	10.7	0
110	Mycobacterial Disease: Evolving Concepts. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 269-269.	2.1	0
111	JCF â€“ progress in 2018. Journal of Cystic Fibrosis, 2019, 18, 1-5.	0.7	0
112	Cystic Fibrosis: Advances in Understanding and Treatment. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 699-700.	2.1	0
113	JCF Year in Review. Journal of Cystic Fibrosis, 2020, 19, 505-506.	0.7	0
114	Pursuit of Equity. Journal of Cystic Fibrosis, 2020, 19, 171.	0.7	0
115	JCF Year in Review. Journal of Cystic Fibrosis, 2021, 20, 1-2.	0.7	0
116	Loss of cilia alters airway epithelial cells and evokes an immune response. FASEB Journal, 2010, 24, 612.4.	0.5	0
117	Providing Restricted Access to an Electronic Medical Record for Research Monitoring. Clinical Researcher, 2018, 32, .	0.5	0
118	From the Editor's Desk. Journal of Cystic Fibrosis, 2022, 21, 197-198.	0.7	0